For a patient on ticagrelor (Brilinta), should enoxaparin (Lovenox) be given for deep vein thrombosis prophylaxis?

Ticagrelor (Brilinta) Does NOT Replace DVT Prophylaxis

Patients on ticagrelor (Brilinta) still require enoxaparin (Lovenox) for DVT prophylaxis if they have standard indications for VTE prevention. Antiplatelet agents like ticagrelor target arterial thrombosis (platelet-mediated), while DVT prophylaxis targets venous thromboembolism (coagulation cascade-mediated)—these are distinct pathophysiologic processes requiring different pharmacologic approaches.

Key Distinction: Arterial vs Venous Thrombosis

Ticagrelor is a P2Y12 inhibitor used for arterial thrombosis prevention in acute coronary syndromes 1, 2. It works by inhibiting platelet aggregation, which is the primary mechanism of arterial clot formation. However, venous thromboembolism (DVT/PE) is predominantly driven by the coagulation cascade, not platelet aggregation. This fundamental difference means antiplatelet therapy provides minimal to no protection against DVT.

When DVT Prophylaxis is Required

Hospitalized patients on ticagrelor need enoxaparin if they meet standard VTE risk criteria:

• Medical patients with severely restricted mobility during acute illness: enoxaparin 40 mg subcutaneously once daily 3, 4
• Surgical patients undergoing major procedures: enoxaparin 40 mg once daily (or 30 mg every 12 hours for orthopedic surgery) 3, 4
• Cancer patients who are hospitalized with major medical illness or reduced mobility: enoxaparin 40 mg once daily 5, 3

The 2020 ASCO guidelines explicitly state that hospitalized patients with major medical illnesses or reduced mobility should receive prophylactic anticoagulation regardless of other medications 3.

Bleeding Risk Considerations

The critical concern is bleeding risk when combining antiplatelet and anticoagulant therapy. However, this does not eliminate the need for DVT prophylaxis—it requires careful risk-benefit assessment:

• Standard prophylactic-dose enoxaparin (40 mg daily) has acceptable bleeding rates even in patients on antiplatelet therapy 6
• The FDA label for enoxaparin specifically warns about concomitant use with platelet inhibitors but does not contraindicate it 4
• If bleeding risk is prohibitively high, mechanical prophylaxis (intermittent pneumatic compression devices) should be used instead of withholding all VTE prevention 6, 7

Practical Algorithm

For patients on ticagrelor requiring hospitalization:

1. Assess VTE risk: Immobilized? Post-surgical? Active cancer? Acute medical illness?
2. If VTE risk is present:
   • Low-moderate bleeding risk: Add enoxaparin 40 mg subcutaneously once daily 3, 4
   • High bleeding risk (active bleeding, severe thrombocytopenia, recent intracranial hemorrhage): Use mechanical prophylaxis (pneumatic compression devices) 6
3. Continue throughout hospitalization or until fully ambulatory 3, 4

Common Pitfall to Avoid

Do not assume that ticagrelor provides DVT protection simply because it is an antithrombotic agent. The 2025 ACC/AHA guidelines clearly distinguish between antiplatelet therapy for ACS and anticoagulation for VTE—these are separate therapeutic goals 1, 2. Failing to provide DVT prophylaxis in at-risk hospitalized patients on ticagrelor leaves them vulnerable to potentially fatal pulmonary embolism.

The only scenario where enoxaparin might be withheld is if bleeding risk clearly outweighs VTE risk, in which case mechanical prophylaxis becomes mandatory 6.